The previous studies of interactions between one ADRA2C and one ADRB1 polymorphism illustrate that the physiological effects of variations in these two genes act synergistically to increase risk of heart failure [20] and influences patient responsiveness to beta-blocker therapy as assessed by short-term improvements in LVEF [21]. Here, ADRB1 is linked to heart failure.